Auxilium On a Roll ...
Health Care: Drugs
Acorda Therapeutics Inc. (ACOR: NASDAQ)
$22.07 0.23 | 1.05%
06/04/12 - 02:48 PM ET
Company Balance Sheet
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 57.95M | 34.64M | 47.31M | 29.61M |
| Receivables | 22.83M | 22.27M | 5.74M | 4.62M |
| Inventories | 28.38M | 38.42M | 6.89M | 6.14M |
| Other Current Assets | 6.99M | 3.73M | 3.98M | 1.61M |
| Total Current Assets | 360.94M | 311.17M | 293.28M | 262.05M |
| Property, Plant & Equipment, Gross | 13.49M | 11.31M | 8.84M | 8.23M |
| Accumulated Depreciation & Depletion | 9.63M | 8.11M | 6.95M | 5.88M |
| Property, Plant & Equipment, Net | 3.86M | 3.20M | 1.89M | 2.35M |
| Intangibles | 8.77M | 21.34M | 17.15M | 16.57M |
| Other Non-Current Assets | 5.92M | 6.39M | 7.15M | 539.33K |
| Total Non-Current Assets | 18.55M | 30.93M | 26.19M | 19.45M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 379.49M | 342.10M | 319.47M | 281.50M |
| Accounts Payable | 29.99M | 16.96M | 11.61M | 10.12M |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 0.00 | 0.00 | 0.00 | 6.18M |
| Total Current Liabilities | 87.34M | 94.25M | 72.90M | 54.60M |
| Long Term Debt | 6.26M | 6.58M | 7.75M | 6.90M |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 80.68M | 90.01M | 101.49M | 12.84M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 86.94M | 96.59M | 109.24M | 19.74M |
| Total Liabilities | 174.28M | 190.84M | 182.14M | 74.34M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 205.21M | 151.26M | 137.33M | 207.16M |
| Common Par | 39.00K | 38.78K | 37.94K | 37.61K |
| Additional Paid In Capital | 614.91M | 591.65M | 565.50M | 550.68M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -409.48M | -440.09M | -428.32M | -344.38M |
| Treasury Stock | -329.00K | -328.76K | 0.00 | 0.00 |
| Other Equity Adjustments | 66.00K | -12.58K | 108.61K | 812.76K |
| Total Capitalization | 211.47M | 157.84M | 145.08M | 214.06M |
| Total Equity | 205.21M | 151.26M | 137.33M | 207.16M |
| Total Liabilities & Stock Equity | 379.49M | 342.10M | 319.47M | 281.50M |
| Total Common Shares Outstanding | 39.33M | 38.77M | 37.94M | 37.61M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 12.42K | 12.42K | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 39.00M | 38.36M | 37.73M | 33.94M |
| Diluted Weighted Shares Outstanding | 40.06M | 38.36M | 37.73M | 33.94M |
| Number of Employees | 328 | 305 | 249 | 174 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with ACOR
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- Contributor13 Biotech Stocks Bought an...
- Contributor5 Biotech Drug-Launch Stock...
- Usergrandpicks
- UserPART 1 JPMorgan 28th Annual...
- ContributorBarron's Research Reports 3...
- UserUndervalued Biotech's
- UserPART 1 JPMorgan 27th Annual...
- UserFerrengi Holdings
Latest ACOR Headlines from TheStreet
- FDA More Problematic Than Obamacare, Says Acorda CEO
04.24.12 | 06:04 am - BIO CEO Confab Live Blog: Day 2 02.14.12 | 10:02 am
- BIO CEO Conference Live Blog 02.13.12 | 01:02 pm
- 8 Stocks Rising on Huge Volume 01.05.12 | 02:01 pm
- Acorda Rises On Unusually High Volume (ACOR) 11.04.11 | 04:11 pm
- Acorda Stock Hits New 52-Week Low (ACOR) 09.29.11 | 01:09 pm
- SAC Upped Dendreon Exposure Before Blowup 08.15.11 | 05:08 pm
- 5 Biotech Drug-Launch Stocks to Watch 07.18.11 | 09:07 am
- Acorda Stock Gaps Up On Today's Open (ACOR) 05.20.11 | 09:05 am
- European Regulators Approve New Drugs 05.20.11 | 07:05 am
Press Releases for ACOR
- Robbins Umeda LLP Announces An Investigation Of Acorda Therapeutics, Inc. - Business Wire 06.04.12 | 11:06 am
- New Research Presented At 4th Collaborative Meeting Of CMSC And ACTRIMS Expands Understanding Of MS-Related Walking Impairment And Clinical Usage Of AMPYRA® - Business Wire 05.31.12 | 06:05 am
- Acorda Therapeutics Launches First-Ever Online Talk Show Focusing On Walking Problems In Multiple Sclerosis - Business Wire 05.30.12 | 07:05 am
- Acorda Therapeutics Recognized As One Of The Best Places To Work In New York State For Second Consecutive Year - Business Wire 04.30.12 | 07:04 am
- Acorda Therapeutics Presents AMPYRA® Long-Term Safety And Efficacy Data At 64th American Academy Of Neurology Annual Meeting - Business Wire 04.25.12 | 07:04 am
- Acorda Therapeutics Named One Of The 100 Most Trustworthy Companies By Forbes - Business Wire 04.12.12 | 07:04 am
- Acorda Therapeutics To Provide Pipeline Update At Upcoming R&D Day - Business Wire 04.10.12 | 07:04 am
- Acorda Therapeutics Launches New Interactive Website Spotlighting Treatment With Ampyra® (Dalfampridine) Of Walking Problems In Patients With Multiple Sclerosis - Business Wire 04.02.12 | 08:04 am
- Acorda Therapeutics To Present At The Cowen & Company 32nd Annual Health Care Conference - Business Wire 02.27.12 | 07:02 am
- Acorda Therapeutics To Present At 2012 RBC Capital Markets' Global Healthcare Conference - Business Wire 02.22.12 | 06:02 am
Partner Headlines for ACOR
- Revenues Climb at Acorda - Analyst Blog - Zacks 05.04.12 | 06:05 pm
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 04.17.12 | 09:04 am
- Biogen's Fampyra Launched in Canada - Analyst Blog - Zacks 04.13.12 | 06:04 pm
- 4 Compelling Alternatives To Vertex Pharma - Seeking Alpha 02.23.12 | 08:02 am
- 5 Stocks Ripe For A Takeover - Seeking Alpha 10.28.11 | 05:10 pm
- Notable Call Options Activity in Acorda Therapeutics - Benzinga 10.13.11 | 01:10 pm
- Company News for October 6, 2011 - Corporate Summary - Zacks 10.06.11 | 10:10 am
- 7 Possible Biotech Takeover Targets - Seeking Alpha 09.18.11 | 08:09 am
- 5 Biotech Takeover / LBO Targets With Bullish Short Trends - Seeking Alpha 07.15.11 | 07:07 pm
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 07.12.11 | 09:07 am
